Beam Therapeutics (BEAM) EPS (Weighted Average and Diluted) (2019 - 2026)
Beam Therapeutics (BEAM) reported EPS (Weighted Average and Diluted) of -$0.91 for Q1 2026, up 26.02% year-over-year from -$0.72 in Q1 2025, and down 136.25% on a QoQ basis from $2.51 in Q4 2025.
Beam Therapeutics (BEAM) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.91 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 26.02% year-over-year to -$0.91 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.5 (up 89.13% YoY) and the FY2025 annual result came in at -$0.81, up 82.31% from the prior year.
- EPS (Weighted Average and Diluted) declined to -$0.91 in Q1 2026 per BEAM's latest filing, from $2.51 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $2.51 in Q4 2025 and bottomed at -$1.56 in Q3 2022.
- The 5-year median for EPS (Weighted Average and Diluted) is -$1.09 (2024), against an average of -$0.72.
- The widest annual swing landed in 2022, when EPS (Weighted Average and Diluted) sank 271.43%; it then jumped 453.7% in 2023.
- Tracing BEAM's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.54 in 2022, then jumped by 453.7% to $1.91 in 2023, then slumped by 157.07% to -$1.09 in 2024, then soared by 330.28% to $2.51 in 2025, then sank by 136.25% to -$0.91 in 2026.
- Per Business Quant, the three latest BEAM EPS (Weighted Average and Diluted) figures stand at -$0.91 (Q1 2026), $2.51 (Q4 2025), and -$1.1 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Beam Therapeutics | 3.40 Bn | 3.40 Bn | - | -0.91 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.91 |
| Dec 31, 2025 | 2.51 |
| Sep 30, 2025 | -1.10 |
| Jun 30, 2025 | -1.00 |
| Mar 31, 2025 | -1.23 |
| Dec 31, 2024 | -1.09 |
| Sep 30, 2024 | -1.17 |
| Jun 30, 2024 | -1.11 |
| Mar 31, 2024 | -1.21 |
| Dec 31, 2023 | 1.91 |
| Sep 30, 2023 | -1.22 |
| Jun 30, 2023 | -1.08 |
| Mar 31, 2023 | -1.33 |
| Dec 31, 2022 | -0.54 |
| Sep 30, 2022 | -1.56 |
| Jun 30, 2022 | -1.02 |
| Mar 31, 2022 | -1.01 |
| Dec 31, 2021 | -0.91 |
| Sep 30, 2021 | -0.42 |
| Jun 30, 2021 | -1.23 |
| Mar 31, 2021 | -3.35 |
| Dec 31, 2020 | -1.88 |
| Sep 30, 2020 | -0.69 |
| Jun 30, 2020 | -0.69 |
| Dec 31, 2019 | -4.80 |